Virios Therapeutics Inc.’s (NASDAQ: VIRI) ($VIRI) interview with Greg Duncan, CEO.


New to The Street TV’s Host Jane King welcomes Greg Duncan, CEO at Virios Therapeutics, Inc. (NASDAQ: VIRI) ($VIRI) (“Virios”) for his in-studio Nasdaq Marketplace interview. Virios is a development-stage biotechnology Company focused on advancing novel antiviral therapies. Greg explains the Company’s focus is on various disorders, including fibromyalgia and irritable bowel disease. The Company’s novel IMC-1 compound is a proprietary combination of famciclovir and celecoxib. The Company completed its fibromyalgia IMC-1 FDA Phase 2a with clinical outcomes. Currently, the fibromyalgia study using IMC-1 is in FDA Phase 2b clinical, a multi-center, randomized, double-blind, placebo-controlled clinical with over 400 patients. The Company expects success in the fibromyalgia Phase 2b study, which then places the IMC-1 into Phase 3 trials. The Company’s management and Board of Directors are a team of successful doctors, scientists, and finance experts. Greg launched many pharmaceutical brands, including Zoloft. Virios develops novel treatments using existing drug combinations to eliminate antiviral conditions that can affect many humans. The on-screen QR code is available during the show; download or visit Virios Therapeutics, Inc. –

To make sure you never miss a video from New to the Street, click here to subscribe:

Follow New to the Street on Twitter:

Follow New to the Street on Facebook:

Follow New to the Street on Instagram:

Follow New to the Street on Rumble:

About New to the Street:

Subscribe to our Mailing List: